PEB.NZX

Pacific Edge Limited

Our view

You need to become a client or login to see Forsyth Barr’s current view.

Recent research View all research

About Pacific Edge Limited

Pacific Edge (PEB) is a cancer diagnostics company in the early stages of commercialising its first product, Cxbladder. Investors continue to require patience, with the large US market challenging to secure reimbursement. Changing established clinical processes takes time, albeit early signs remain encouraging. PEB is a speculative risk stock, reliant on converting key groups to commercial customers, with timing highly unpredictable. Its cash balance offers limited flexibility, however, the prize is large and things could change quickly.

Forsyth Barr Analyst

Share price performance

All stock prices and news delayed 20 minutes

09:06 April 26th 2019 NZST

0.29 0.0%

0.29 Buy

0.30 Sell

Last --

Open --

High --

Low --

Volume -

Turnover -

Most recent trades All trades for the day

Time Price Volume Value

Latest Pacific Edge Limited research

Show more results

Today's trades

Trade Number Time Price Volume Value

Latest Pacific Edge Limited news

If you're new to investing or just have a question please call us: 0800 367 227